- Country: USA
- Summary: Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
- UST Ref No: 112116611
- Deadline: 16 Jan 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: HT9402-25-Q-9103
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish aneff ective, eff icient, integrated pharmacy benefits program for the Military Health System(MHS) which includes the purchase pharmaceutical agents. The law and implementingregulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy andTherapeutics (P&T) Committee will consider the relative clinical eff ectiveness and relativecost eff ectiveness of pharmaceutical agents in a therapeutic class in recommending theselection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, theclassification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF),Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&TCommittee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within DrugClasses identified for placement on the UF has been issued to obtain quotes from industry.The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements(UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP)based on the UF decision. This process is described in the attached RFQ.P&T COMMITTEE MEETING: The following February 2025 newly approved drugs will be reviewed:
The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions,important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9103.
a. Attruby - Neurological Agents Misc - NAb. Danziten - Oncological Agents - NAc. Emrosi - Antibiotics - Tetracyclinesd. Hympavzi - Antihemophilic Factors - NAe. Nypozi - White Blood Cell Stimulants - Filgrastimsf. Omnipod 5 Libre2Plus G6 - Insulins - Miscellaneous Insulin Deviceg. Revuforj - Oncological Agents - NA
Pre-quotation teleconference is on January 8, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submittedvia e-mail to the RFQ ... - Documents:
Price-List-Attruby-Neurological-Agents-Misc.xlsx
Price-List-Danziten-Oncological-Agents-NA.xlsx
Price-List-Emrosi-Antibiotics-Tetracyclines.xlsx
Price-List-Hympavzi-Antihemophilic-Factors-N.xlsx
Price-List-Nypozi-White-Blood-Cell-Stimulants.xlsx
Price-List-Omnipod-5-Libre2Plus-G6-Insulins.xlsx
Price-List-Revuforj-Oncological-Agents-NA.xlsx
DoD-Formulary-Placement-of-FDA-Newly-Approved-Drug.pdf
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINDepartment of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program - USA Tender
The DEPT OF DEFENSE | DEFENSE HEALTH AGENCY (DHA), a Government sector organization in USA, has announced a new tender for Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program. This tender is published on USARFP under UST Ref No: 112116611 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-01-16.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
